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Therapeutic plasma exchange pheresis (plasmapheresis) has become a widely accepted therapeutic modality for a number of autoimmune illnesses as well as certain illnesses of presumed or proven infectious etiology (4, 5) . The influence of plasmapheresis on the elimination of antibiotics is largely unknown. Prince et al. (6) noted more than 30% reduction in ampicillin and gentamicin concentrations in serum from septic neonates treated with exchange transfusions. The elimination kinetics of a single 2-g intravenous dose of ceftazidime were recently studied in 11 patients with various autoimmune diseases and who were treated with plasmapheresis (2). Only 2 to 9% of the administered dose was removed by plasmapheresis, suggesting that the dosage of ceftazidime should be determined solely by monitoring renal function (2) .
We recently cared for a young man who was treated with intravenous ceftriaxone and plasmapheresis for presumed neurological Lyme disease. This report describes the influence of plasmapheresis on the elimination kinetics of maintenance ceftriaxone therapy.
A 25-year-old homosexual male presented with urinary retention and paresthesias of the lower extremities 7 days after an influenzalike illness. Past medical history was pertinent for migraine headaches over the past 4 years and nephrolithiasis 2 years previously. There was no past or recent history of tick bites. His temperature at admission was normal. The general and neurological examination revealed a dilated urinary bladder (residual volume, 900 ml), mild nuchal rigidity, and paresthesias of both lower extremities. Admission urinalysis, complete blood cell count, and multianalyzer chemistry profile were all normal. The erythrocyte sedimentation rate was 10 mm/h, and C-reactive protein was 1.3 mg/dl (normal is <0.8 mg/dl). Lumbar puncture demonstrated mild mononuclear pleocytosis in the cerebrospinal fluid as well as mild protein elevation in the cerebrospinal fluid. The cerebrospinal fluid/serum glucose ratio was normal. The basic myelin protein in cerebrospinal fluid was elevated at 19 ng/ml (normal is <4.0 ng/ml).
Venereal Disease Research Laboratory, fluorescent antinuclear antibody, and mycoplasma immunoglobulin M tests as well as acute and convalescent viral serology (including human immunodeficiency virus enzyme immunoassay, human T-lymphotropic virus, herpes simplex virus, EpsteinBarr virus, and enterovirus) were all negative or nonreactive. An initial Lyme enzyme immunoassay titer was mildly * Corresponding author. elevated, and the patient began treatment with intravenous ceftriaxone 2 g every 24 h (30-min infusions) for suspected Borrelia burgdorferi-associated transverse myelitis.
Over the next week the patient's headaches intensified. He developed paraparesis, and the dermatomal level of his paresthesias progressed cephalad to T7. It was therefore decided to institute daily plasmapheresis over a 3-day period and during ongoing ceftriaxone therapy. The plasma exchanges began on day 6 of ceftriaxone therapy, employing a Senwal PS 400 plasma exchange machine (continuous flow). Each plasmapheresis began circa 12 h after the ceftriaxone infusion and lasted for 150 min. Equal volumes of human albumin replaced his daily 3-liter plasma volume loss. Blood samples for ceftriaxone plasma concentrations were collected in heparinized test tubes at 30 min before and 60 min after the start of the ceftriaxone infusion as well as immediately before and after plasmapheresis. Ceftriaxone concentrations in plasma were analyzed in triplicate by using a microbiological assay with human plasma as the control diluent and Escherichia coli ATCC 25922 as the indicator organism. The results of the actual (measured) concentrations in plasma and the projected trough values for days 2 and 3 of plasmapheresis are shown in Fig. 1 . Assuming a first-order ceftriaxone elimination process, pharmacokinetic parameters (elimination constants and elimination half-lives) were determined as described by Sawchuk et al. (7) ( Table  1) .
The clinical recovery in our patient was slow and was not influenced by ceftriaxone or plasmapheresis. The sensory deficits had resolved after 6 weeks, and he was discharged to his home with mild paraparesis.
Some variation was registered between the plasma elimination curves from each day (Fig. 1 shown]), explained by the fact that part of the plasma removed was drug-free albumin supplied for the exchange.
It is likely that the majority of the ceftriaxone load was to be found in the interstitial compartment at the time when plasmapheresis started (3). Since ceftriaxone is highly protein bound, drug mobilization from the interstitium to the vascular compartment would expectedly be slow. A reverse distribution of ceftriaxone (rebound effect) from interstitium to plasma could theoretically take place in the first hour after plasmapheresis. If so, this would tend to overestimate the elimination constant during the procedure in this case study. No late plasma sample was obtained to evaluate this possibility.
Even though up to 67% of a ceftriaxone dose may be eliminated via biliary excretion (1), it is unlikely that significant drug concentrations could be returned to the vascular space through the enterohepatic circulation. A study by Stoeckel et al. (8) showed that ceftriaxone excreted in bile becomes microbiologically inactivated, and virtually no ceftriaxone is reabsorbed from the intestinal tract (Stoeckel, personal communication) . The impact of the daily removal of 3 liters of plasma had little influence on the total ceftriaxone clearance; only 3.7 and 10.6% deficits were registered when actual trough levels in plasma were compared with expected levels. Thus, no drug dosage adjustments appear necessary when plasmapheresis is performed within 12 h of redosing. Further research is currently being conducted to determine the dialytic clearance of ceftriaxone in patients treated with plasmapheresis, the extent of a possible postpheresis rebound effect, and whether plasmapheresis adversely affects the early elimination curve of ceftriaxone, necessitating redosing shortly after the plasma exchange.
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